AIR LIQUIDE AMERICA SPECIALITY GASES
PharmaAIR LIQUIDE AMERICA SPECIALITY GASES is a pharmaceutical company with 2 FDA-approved products.
AIR LIQUIDE AMERICA SPECIALITY GASES's Key Drugs
AIR LIQUIDE AMERICA SPECIALITY GASES's core commercial portfolio centers on MEDICAL AIR, USP, NITROUS OXIDE, USP — its most strategically important drugs approved in the last 15 years.
AIR LIQUIDE AMERICA SPECIALITY GASES's Recent FDA Approvals
AIR LIQUIDE AMERICA SPECIALITY GASES secured 2 new FDA approvals for novel drugs (NDA/BLA) in the last two years.
AIR LIQUIDE AMERICA SPECIALITY GASES's Therapeutic Areas
Disease areas where AIR LIQUIDE AMERICA SPECIALITY GASES has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
AIR LIQUIDE AMERICA SPECIALITY GASES Pipeline Snapshot
Active clinical trials for AIR LIQUIDE AMERICA SPECIALITY GASES across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • MEDICAL AIR, USP leads revenue
- • 2 key drugs tracked
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (2)
Discontinued (0)
Company Info
- First Approval
- 2013-06-16
- Latest
- 2013-06-16
- Applications
- 2